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1. INTRODUCTION {#cam41721-sec-0001}
===============

Thyroid cancer remains the most prevalent malignant endocrine disorder with low mortality but increased incidence and recurrence. According to the United States cancer statistics, approximately 726 646 people lived with thyroid cancer in 2014, and there would be 56 870 new cases diagnosed as thyroid cancer in 2017.[1](#cam41721-bib-0001){ref-type="ref"} Moreover, by 2030, thyroid cancer was expected to be the fourth leading cancer diagnosis.[2](#cam41721-bib-0002){ref-type="ref"} Papillary thyroid cancer (PTC) is the most common pathological type, accounting for 80% of thyroid cancer. In the long run, the prognosis of PTC is excellent and the 5‐year survival rate could reach 98.2%; however, its recurrence rate is relatively high.[3](#cam41721-bib-0003){ref-type="ref"}, [4](#cam41721-bib-0004){ref-type="ref"} On the other hand, anaplastic thyroid cancer (ATC) is less frequent even if it has more aggressive biological behavior and worse prognosis. Recent studies showed that genetic and epigenetic alterations were involved in PTC pathogenesis and could be markers for prognosis, such as BRAF mutations,[5](#cam41721-bib-0005){ref-type="ref"}, [6](#cam41721-bib-0006){ref-type="ref"}, [7](#cam41721-bib-0007){ref-type="ref"} RAS mutations,[8](#cam41721-bib-0008){ref-type="ref"}, [9](#cam41721-bib-0009){ref-type="ref"} and RET rearrangements.[10](#cam41721-bib-0010){ref-type="ref"}, [11](#cam41721-bib-0011){ref-type="ref"}

LncRNAs are described as transcripts with longer than 200 nucleotides without translation function. It plays an essential part in the regulation of gene transcription, post‐transcription, and epigenetic modulation.[12](#cam41721-bib-0012){ref-type="ref"}, [13](#cam41721-bib-0013){ref-type="ref"}, [14](#cam41721-bib-0014){ref-type="ref"} Amounting evidence indicate that lncRNAs are crucial in oncogenesis and tumor development.[15](#cam41721-bib-0015){ref-type="ref"}, [16](#cam41721-bib-0016){ref-type="ref"}, [17](#cam41721-bib-0017){ref-type="ref"} It was also found that plenty of lncRNAs was differentially expressed in thyroid cancer compared with normal adjacent tissues. These lncRNAs were expected to be correlated with diagnosis and prognosis of PTC.[18](#cam41721-bib-0018){ref-type="ref"}

The competing endogenous RNA (ceRNA) hypothesis was first proposed about how messenger RNAs (mRNAs), transcribed pseudogenes, and lncRNAs connect to each other using microRNA response elements (MREs).[19](#cam41721-bib-0019){ref-type="ref"} Recently, ceRNA hypothesis was proved to be essential in physiologic and pathological conditions such as cancer.[20](#cam41721-bib-0020){ref-type="ref"}

Thousands of lncRNAs were found aberrantly expressed in PTC samples compared with normal thyroid tissues using genomewide analysis.[21](#cam41721-bib-0021){ref-type="ref"} With further research, more and more lncRNAs were found to be closely related to the initiation and development of PTC. For instance, 218 aberrantly expressed lncRNAs were identified in genomewide expression screening, and two lncRNAs (XLOC‐051122 and XLOC‐006074) were found significantly related to lymphatic metastasis.[22](#cam41721-bib-0022){ref-type="ref"} Another study performed by Li et al[23](#cam41721-bib-0023){ref-type="ref"} described four lncRNAs signature (RP11‐536N17.1, RP11‐508M8.1, AC026150.8, and CTD‐2139B15.2) predicting PTC prognosis. Differentially expressed RNAs in 348 cases were identified in three PTC variants and were selected to construct the ceRNA network by Yanjing Zhao.[24](#cam41721-bib-0024){ref-type="ref"} However, the ceRNA network of PTC is still poorly investigated in a larger cohort, and the validation analysis needs to be performed. In this study, dysregulated RNAs (including lncRNAs, miRNAs, and mRNAs) were detected in different stages and lymph node status, and these RNAs were used to construct the ceRNA network of PTC. Next, quantificational real‐time polymerase chain reaction (qRT‐PCR) validation was performed to confirm the credibility of bioinformatics analysis results. GO terms and KEGG pathways were performed to identify the differentially expressed mRNAs. Our results indicate that ceRNA network plays an important part in the development of PTC, and the study also provides a novel perspective for the better understanding of lncRNA‐miRNA‐mRNA interactions in PTC initiation and development.

2. MATERIALS AND DESIGN {#cam41721-sec-0002}
=======================

2.1. Patients and samples {#cam41721-sec-0003}
-------------------------

Our study was granted approval by the ethics committee of Nanjing Drum Tower Hospital. Firstly, we collected 503 PTC cases and 59 normal thyroid cases from the The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>). Then, we set the exclusion criteria as below: (a) pathologic diagnosis is not PTC; (b) suffering from other cancers except PTC; (c) patients samples without integrated clinical information. Overall, 461 PTC tumor cases and 55 normal thyroid cases were identified in the study. On the basis of the 7th American Joint Committee on Cancer (AJCC) TNM staging system, among these 461 patients with PTC, there were 256 patients with stage I PTC, 51 patients with stage II PTC, 104 patients with stage III PTC, and 50 patients with stage IV PTC. Additionally, there are 219 PTC cases with lymphatic metastasis and 242 PTC cases without lymphatic metastasis.

Additionally, 28 paired frozen PTC samples (thyroid tumor samples and adjacent normal thyroid samples) were obtained from Nanjing Drum Tower Hospital for qRT‐PCR. Tissues were immersed in RNAlater (GenStar BioSolutions, Beijing, China) immediately after surgical resection and stored at −80°C until use. Pathology reports and quality assessment reports were required to verify the collected tumor tissues and normal thyroid tissues. Demographic and clinical features of these patients were shown in Table [1](#cam41721-tbl-0001){ref-type="table"}. Informed consent agreements were signed by all patients in this study.

###### 

Demographic and clinical features of 28 patients with PTC

  Parameters           Cohort (n = 28) %
  -------------------- -------------------
  Age (mean ± SD)      39.8 ± 9.8
  Gender               
  Female               20 (71.4)
  Male                 8 (28.6)
  Pathologic staging   
  I‐II                 22 (78.6)
  III‐IV               6 (21.4)
  Tumor size           
  T1‐T2                17 (60.7)
  T3‐T4                11 (39.3)
  Lymph node           
  N0                   10 (35.7)
  N1                   18 (64.3)
  Metastasis           
  M0                   28 (100)
  M1                   0 (0)
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2.2. RNA sequence data analysis {#cam41721-sec-0004}
-------------------------------

Firstly, we obtained all RNA expression profiles (level 3) of patients with PTC from the TCGA data portal (up to May 05, 2016). The raw data of lncRNAs and mRNAs were processed and normalized by TCGA RNASeqv2 system. The PTC level 3 miRNA data were normalized and provided by Illumina HiSeq 2000 microRNA sequencing platforms (Illumina Inc., Hayward, CA, USA). No further normalization was needed as all the RNA sequencing data have already been normalized already. Then, all samples collected in TCGA were divided into three groups to perform the differential analysis of lncRNAs, miRNAs, and mRNAs. Thus, all collected samples were grouped as: (a) PTC tumor samples and normal thyroid samples; (b) PTC samples with lymphatic metastasis and PTC samples without lymphatic metastasis; (c) PTC samples with stages I‐II and PTC samples with stages III‐IV. Four groups were listed as follows: stages I‐II with/without lymphatic metastasis and stages III‐IV with/without lymphatic metastasis, and these groups contained 112, 195, 107, and 47 cases, respectively. The intersected lncRNAs, miRNAs, and mRNAs were then chosen to construct the ceRNA network which shows the genetic regulation related to PTC. The bioinformatics analysis is illustrated in the flowchart (Figure [1](#cam41721-fig-0001){ref-type="fig"}).

![The flowchart of bioinformatics analysis](CAM4-7-5394-g001){#cam41721-fig-0001}

2.3. Gene functional enrichment analysis {#cam41721-sec-0005}
----------------------------------------

The intersected mRNAs were selected following the above methods and were analyzed to detect the potential biologic functions and pathways. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics resources (<http://david.abcc.ncifcrf.gov/>) were employed to analyze the potential functions and pathways. The biological functions and pathways were considered significant when an enrichment score of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis exceeds 1.5 (*P* \< 0.05).

2.4. The ceRNA network in PTC {#cam41721-sec-0006}
-----------------------------

The interactions among lncRNAs, miRNAs, and mRNAs contribute to the post‐transcriptional regulation of mRNAs. The ceRNA network is built based on miRNA sponge[25](#cam41721-bib-0025){ref-type="ref"} in our study. This theory indicates that lncRNAs conjunct with miRNAs to regulate mRNAs expression. Furthermore, the miRNA‐lncRNA and miRNA‐mRNA relationships were collected in the starBase v2.0 database (<http://starbase.sysu.edu.cn/>),[26](#cam41721-bib-0026){ref-type="ref"} and only differentially expressed intersection lncRNAs, miRNAs, and mRNAs with fold change (FC) \>2.0 or FC \<0.5 and *P* \< 0.05 were selected. Subsequently, miRanda tools (<http://www.microrna.org/microrna/home.do>), the miRNAs target prediction tool, were employed to detect the lncRNA‐miRNA interactions. Then, the mRNA‐miRNA interactions were analyzed by miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>) and TargetScan (<http://www.targetscan.org/>). The summary results were identified to determine the specific interacted lncRNAs and mRNAs. Then, according to ceRNA theory, the negatively regulated lncRNA‐miRNA and mRNA‐miRNA pairs were analyzed in the ceRNA network in PTC.[27](#cam41721-bib-0027){ref-type="ref"} Finally, the ceRNA network was built using Cytoscape v3.0.[28](#cam41721-bib-0028){ref-type="ref"} The ceRNA network construction is illustrated in a flowchart (Figure [2](#cam41721-fig-0002){ref-type="fig"}).

![The flowchart of ceRNA network analysis](CAM4-7-5394-g002){#cam41721-fig-0002}

2.5. Clinical features analysis and qRT‐PCR verification {#cam41721-sec-0007}
--------------------------------------------------------

Specific lncRNAs involved in ceRNA network and bioinformatics analysis were selected to assess the clinical characteristics including age, race, gender, lymphatic metastasis, TNM staging system, and patient outcome in TCGA. In addition, qRT‐PCR validation of eight randomly selected lncRNAs in 28 paired frozen tissues was performed to examine the credibility of the bioinformatics analysis results.

Following the manufacturer\'s protocol, total RNAs were extracted and purified using TRIzol reagent (Pufei, Shanghai, China). Then, concentration and purity of total RNA were detected by the spectrophotometer from BioTek (Shoreline, WA, USA). According to the manufacturer\'s protocol, a total of 1000 ng RNA was used to perform cDNA synthesis, and reverse transcription reaction was conducted using PrimeScript™ from Takara (Dalian, China). Candidate lncRNA expression was amplified with TAKARA SYBR^®^ Premix Ex Taq™ (Dalian, China) on an Applied Biosystems ViiA™ 7 System (Foster City, CA, USA) using specific primers in duplicate. All primers were designed and synthesized by Generay Biotech (Shanghai, China), and the sequences of selected lncRNAs primers were presented in Table [2](#cam41721-tbl-0002){ref-type="table"}. qPCR primers were determined to anneal at 60°C according to the instructions. The comparative CT method was used to measure the relative expression of candidate lncRNAs.[29](#cam41721-bib-0029){ref-type="ref"} β‐actin is used as the internal control in our experiment. FC values were shown as 2^−∆∆Ct^, where ∆∆Ct = (Ct~RNAs~ − Ct~β‐actin~)~tumor~ − (Ct~RNAs~ − Ct~β‐actin~)~adjacent\ normal\ samples~.

###### 

The sequences of eight lncRNAs primers

                 Forward primer (5′→3′)     Reverse primer (5′→3′)
  -------------- -------------------------- --------------------------
  β‐ACTIN        CTACCTCATGAAGATCCTCACCGA   TTCTCCTTAATGTCACGCACGATT
  LOC100130238   CAAAACGAAACCCCTTACTGC      ATCCCCTAGATCAAGCCATGC
  HAND2‐AS1      GGAGTCACAGGCAGTCGTAGA      GAAGGCACAGATCATTCATGG
  MIR9‐3HG       CTCTGCCCTCCTACTTACGCT      CTGCTGGTCATCTGCATTCCT
  LOC143666      CTCCCTGTGGTGCTTGAATGA      TCTACCGCTATCTACTACGAACTT
  EGFEM1P        AATTGAGACACTGGAAGGTGAT     TTGAGTAGCGGTTGATTTGGT
  LINC00284      AGGTTTCCCTCCTTGGCTTAC      TCACATCAGGTCCTTTGCTCC
  TINCR          CCACTGTCATCTCCCCTCTTT      TCTCCCTCCCTATCTTCCATT
  ABCC6P1        TACAGAAACTGCCAGGTCAAG      AGAAGACAGAGGAGCAGACAAA
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2.6. Statistical analysis {#cam41721-sec-0008}
-------------------------

The Student\'s *t* test was performed to detect the statistical significance for two groups, and ANOVA for multiple groups using the GraphPad Prism 6.0. All data are expressed as mean ± SD (standard deviation). The threshold of false discovery rate (FDR) was set as 0.001 to reduce the false positives in multiple tests in bioinformatics analysis, and the threshold of *P* value was set as 0.05 to evaluate the null hypothesis. Box plots were used to present the FC and clinical relevance of the specific lncRNAs in donor samples. The upper and lower boundaries of the boxplots are at 25th and 75th percentiles. The vertical lines below and above the box represent the minimum and the maximum. And the band inside the box is always the median.

3. RESULTS {#cam41721-sec-0009}
==========

3.1. PTC‐specific lncRNAs {#cam41721-sec-0010}
-------------------------

Totally, 1806 lncRNAs were identified from TCGA database (Data [S1](#cam41721-sup-0001){ref-type="supplementary-material"}). We compared the expression of lncRNAs in 461 patients with PTC tumor tissues with adjacent normal tissues and identified 199 differentially expressed lncRNAs (FC \> 2, *P* \< 0.01). Further analysis was carried out between tumor tissues and adjacent normal thyroid tissues on tumor stages and lymph node status. For patients without lymphatic metastasis, there are 99 aberrant expression lncRNAs between stages I‐II PTC tumors samples and normal thyroid samples, and 122 aberrant expression lncRNAs between stages III‐IV PTC tumors samples and normal thyroid samples. For patients with lymphatic metastasis, 160 aberrant expression lncRNAs were identified between stages I‐II PTC tumors samples and normal thyroid samples, and 177 aberrant expression lncRNAs were identified between stages III‐IV PTC tumors samples and normal thyroid samples (Figure [3](#cam41721-fig-0003){ref-type="fig"}A). The intersected 83 specific intersected lncRNAs were selected initially for further analysis on ceRNA network to improve the credibility of bioinformatics analysis results (Table [3](#cam41721-tbl-0003){ref-type="table"}).

![Venn diagram analysis of differentially expressed (A) lncRNAs, (B) mRNAs, and (C) miRNAs between I‐II Lym/Normal, I‐II nLym/Normal, III‐IV Lym/Normal, and III‐IV nLym/Normal. Lym, lymph node metastasis; nLym, nonlymph node metastasis; normal represents adjacent nontumor thyroid tissues](CAM4-7-5394-g003){#cam41721-fig-0003}

###### 

Differentially expressed intersection lncRNAs between I‐II Lym/Normal, I‐II nLym/Normal, III‐IV Lym/Normal, and III‐IV nLym/Normal

  lncRNAs        Gene ID     Regulation   Average FC
  -------------- ----------- ------------ ------------
  LOC400794      400794      Up           55.465
  RPSAP52        204010      Up           15.625
  TINCR          257000      Up           11.360
  ABCC6P1        653190      Up           8.105
  PRSS3P2        154754      Up           7.165
  EGFEM1P        93 56       Up           6.810
  NR2F1‐AS1      441094      Up           6.600
  FLJ16779       100192386   Up           6.365
  MIR31HG        554202      Up           6.095
  MIR924HG       647946      Up           5.490
  LINC00284      121838      Up           5.455
  ABHD11‐AS1     171022      Up           5.190
  FBLL1          345630      Up           4.650
  CYP1B1‐AS1     285154      Up           4.585
  LOC100126784   100126784   Up           4.585
  FLJ23867       200058      Up           4.290
  LINC00887      100131551   Up           4.130
  YWHAEP7        284100      Up           4.060
  SFTA1P         207107      Up           3.955
  LOC93429       93429       Up           3.935
  LOC441204      441204      Up           3.865
  FER1L4         80307       Up           3.860
  HCG22          285834      Up           3.595
  GGT8P          645367      Up           3.465
  FOXD2‐AS1      84793       Up           3.340
  PP14571        100130449   Up           3.260
  EGOT           100126791   Up           3.255
  ABCC6P2        730013      Up           3.035
  LBX2‐AS1       151534      Up           2.880
  FCGR1CP        100132417   Up           2.760
  SMIM10L2A      399668      Up           2.740
  GGT3P          2679        Up           2.725
  KRTAP5‐AS1     338651      Up           2.590
  LINC00152      112597      Up           2.575
  CYP2B7P        1556        Up           2.450
  DLEU2          8847        Up           2.345
  LOC285629      285629      Up           2.255
  MBL1P          8512        Up           2.240
  ESPNP          284729      Up           2.210
  LINC01366      257358      Up           2.150
  PLEKHA8P1      51054       Up           2.125
  AADACP1        201651      Down         −11.976
  LINC00473      90632       Down         −11.236
  SLC26A4‐AS1    286002      Down         −10.582
  TPTE2P1        646405      Down         −10.363
  LOC100130238   100130238   Down         −10.152
  FAM167A‐AS1    83656       Down         −7.143
  LINC01139      339535      Down         −7.143
  TDH            157739      Down         −5.128
  HAND2‐AS1      79804       Down         −5.000
  LINC00092      100188953   Down         −4.762
  LINC01257      116437      Down         −4.444
  VLDLR‐AS1      401491      Down         −4.348
  LOC143666      143666      Down         −4.348
  DPY19L2P4      442523      Down         −4.167
  MIR9‐3HG       254559      Down         −4.082
  LINC00982      440556      Down         −4.082
  B3GALT5‐AS1    114041      Down         −3.846
  LINC01550      388011      Down         −3.774
  GOLGA8IP       283796      Down         −3.571
  LINC00602      441177      Down         −3.509
  MIR4697HG      283174      Down         −3.448
  FAM181A‐AS1    283592      Down         −3.448
  ANKRD20A8P     729171      Down         −3.390
  ATP6V0E2‐AS1   401431      Down         −3.279
  FAM95B1        100133036   Down         −3.125
  LINC00652      29075       Down         −3.030
  SNORD116‐4     100033416   Down         −3.030
  ST7‐AS1        93653       Down         −2.817
  LINC01140      339524      Down         −2.817
  TERC           7012        Down         −2.778
  PWAR5          8123        Down         −2.778
  LINC01126      100129726   Down         −2.740
  MIR22HG        84981       Down         −2.667
  ZNF826P        664701      Down         −2.667
  LRRC37A6P      387646      Down         −2.632
  PGM5‐AS1       572558      Down         −2.632
  LINC00261      140828      Down         −2.597
  LINC00936      338758      Down         −2.597
  FAR2P1         440905      Down         −2.597
  AGPAT4‐IT1     79992       Down         −2.532
  SNORD116‐20    100033431   Down         −2.532
  GVINP1         387751      Down         −2.353

83 PTC‐specific lncRNAs for ceRNA network construction with absolute fold change (FC) \>2.0, *P* \< 0.05. I, II, III, and IV, TNM stages I, II, III, and IV. Lym, lymph node metastasis; nLM, nonlymph node metastasis; normal represents adjacent nontumor thyroid tissues.
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3.2. Functional enrichment analysis {#cam41721-sec-0011}
-----------------------------------

DAVID bioinformatics resources were employed to predict the biological functions and pathways of aberrantly expressed intersection mRNAs. A total of 18 633 mRNAs was identified from TCGA database, and 3531 mRNAs were aberrantly expressed in PTC tumor samples compared with normal thyroid samples (FC \>2, *P* \< 0.01). For patients without lymphatic metastasis, 2209 aberrant expression mRNAs were identified between stages I‐II PTC tumors samples and normal thyroid samples, and 2457 aberrant expression mRNAs were identified between stages III‐IV PTC tumors samples and normal thyroid samples. For patients with lymphatic metastasis, 2903 aberrant expression mRNAs were identified between stages I‐II PTC tumors samples and normal thyroid samples, and 3128 aberrant expression mRNAs were identified between stages III‐IV PTC tumors samples and normal thyroid samples. Finally, we identified 1822 mRNAs from the intersection of the four groups for further functional analysis.

The upregulation and downregulation of these intersected mRNAs were further analyzed, respectively. GO analysis revealed 531 biological processes corresponding to these upregulated genes and 692 biological processes corresponding to these downregulated genes. Cell adhesion (GO:0007155) was the most enriched function for both upregulation and downregulation transcripts (Figure [4](#cam41721-fig-0004){ref-type="fig"}). KEGG pathway indicated 100 pathways matching with upregulated genes, and the top pathway was neuroactive ligand‐receptor interaction. Furthermore, pathway analysis showed 101 pathways matching with downregulated genes and the top pathway was pathways in cancer (Figure [5](#cam41721-fig-0005){ref-type="fig"}). Among these pathways, "MAPK signaling pathway" has already been demonstrated as the main cause of genetic alterations and PTC development. Targeting "MAPK signaling pathway" has shown an effective antitumor effect in preclinical studies and ongoing clinical trials.[30](#cam41721-bib-0030){ref-type="ref"}

![Top 25 enrichment of GO terms for differentially expressed intersection mRNAs (the bar plot shows the enrichment scores of the significant top 25 enrichment GO terms)](CAM4-7-5394-g004){#cam41721-fig-0004}

![Top 25 enrichment of pathways for differentially expressed intersection mRNAs (the bar plot shows the enrichment scores of the significant enrichment pathways)](CAM4-7-5394-g005){#cam41721-fig-0005}

3.3. Prediction of miRNAs targets and construction of ceRNA network {#cam41721-sec-0012}
-------------------------------------------------------------------

A total of 1030 miRNAs were obtained from TCGA database to identify potential differentially expressed miRNAs. And it was found that 87 miRNAs were aberrantly expressed in PTC tumor samples compared with normal thyroid samples (FC \> 2, *P* \< 0.05). According to the comparisons of four groups described above, 36 miRNAs were selected from the intersections of 87 PTC‐associated miRNAs to build the ceRNA network. Consequently, miRNAs target prediction including lncRNAs and mRNAs were conducted following the instructions described above. Firstly, 83 intersected lncRNAs and 36 specific miRNAs were collected to analyze the potential relationship in PTC. The potential miRNA‐lncRNA interactions were predicted using StarBase v2.0 which could explore the candidate MREs. Finally, according to the analysis results, there were 29 specific miRNAs interacting with 54 specific lncRNAs (Table [4](#cam41721-tbl-0004){ref-type="table"}).

###### 

miRNAs that may target PTC‐specific lncRNAs

  lncRNAs        miRNAs
  -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ABCC6P1        hsa‐miR‐214‐3p
  ABCC6P2        hsa‐miR‐214‐3p
  ABHD11‐AS1     hsa‐miR‐34a‐5p
  AGPAT4‐IT1     hsa‐miR‐214‐3p
  ANKRD20A8P     hsa‐miR‐221‐5p, hsa‐miR‐9‐5p
  ATP6V0E2‐AS1   hsa‐miR‐204‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐9‐5p
  CDC14C         hsa‐miR‐9‐5p
  CYP2B7P        hsa‐miR‐138‐5p, hsa‐miR‐214‐3p
  DLEU2          hsa‐miR‐187‐3p, hsa‐miR‐199a‐3p
  DPY19L2P4      hsa‐miR‐146b‐5p
  EGFEM1P        hsa‐miR‐138‐5p, hsa‐miR‐181a‐5p, hsa‐miR‐181b‐5p, hsa‐miR‐214‐3p, hsa‐miR‐222‐5p, hsa‐miR‐363‐3p, hsa‐miR‐509‐3p
  EGOT           hsa‐miR‐214‐3p
  FAM181A‐AS1    hsa‐miR‐138‐5p, hsa‐miR‐514a‐3p
  FAM95B1        hsa‐miR‐146b‐3p
  FAR2P1         hsa‐miR‐138‐5p, hsa‐miR‐146b‐3p, hsa‐miR‐199a‐3p, hsa‐miR‐214‐3p, hsa‐miR‐221‐3p, hsa‐miR‐221‐5p, hsa‐miR‐222‐3p, hsa‐miR‐3065‐5p
  FCGR1CP        hsa‐miR‐138‐5p
  FER1L4         hsa‐miR‐138‐5p, hsa‐miR‐146b‐3p, hsa‐miR‐187‐3p, hsa‐miR‐34a‐5p, hsa‐miR‐7‐5p
  FLJ16779       hsa‐miR‐138‐5p, hsa‐miR‐181a‐2‐3p, hsa‐miR‐187‐3p, hsa‐miR‐214‐3p, hsa‐miR‐221‐5p,
  FLJ23867       hsa‐miR‐214‐3p
  FOXD2‐AS1      hsa‐miR‐214‐3p
  GGT3P          hsa‐miR‐138‐5p, hsa‐miR‐199a‐3p, hsa‐miR‐214‐3p
  GGT8P          hsa‐miR‐214‐3p
  GVINP1         hsa‐miR‐144‐5p, hsa‐miR‐146b‐3p, hsa‐miR‐181a‐5p, hsa‐miR‐181b‐5p, hsa‐miR‐199a‐3p, hsa‐miR‐204‐5p, hsa‐miR‐214‐3p, hsa‐miR‐3065‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐508‐3p, hsa‐miR‐7‐5p, hsa‐miR‐9‐5p
  HAND2‐AS1      hsa‐miR‐138‐5p, hsa‐miR‐144‐5p, hsa‐miR‐146b‐5p, hsa‐miR‐204‐5p, hsa‐miR‐509‐3p, hsa‐miR‐514a‐3p
  KRTAP5‐AS1     hsa‐miR‐146b‐3p, hsa‐miR‐199b‐5p
  LBX2‐AS1       hsa‐miR‐675‐3p
  LINC00261      hsa‐miR‐138‐5p, hsa‐miR‐146b‐3p, hsa‐miR‐204‐5p, hsa‐miR‐222‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐9‐5p
  LINC00284      hsa‐miR‐9‐5p
  LINC00652      hsa‐miR‐214‐3p
  LINC00887      hsa‐miR‐138‐5p, hsa‐miR‐181b‐5p, hsa‐miR‐204‐5p
  LINC00982      hsa‐miR‐146b‐3p, hsa‐miR‐34a‐5p, hsa‐miR‐9‐5p
  LINC01140      hsa‐miR‐138‐5p, hsa‐miR‐146b‐3p, hsa‐miR‐181b‐5p, hsa‐miR‐204‐5p, hsa‐miR‐214‐3p
  LINC01257      hsa‐miR‐34a‐5p
  LINC01366      hsa‐miR‐34a‐5p
  LINC01550      hsa‐miR‐675‐3p
  LOC100126784   hsa‐miR‐1247‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐451a, hsa‐miR‐7‐5p
  LOC100130238   hsa‐miR‐34a‐5p
  LOC143666      hsa‐miR‐34a‐5p
  LOC285629      hsa‐miR‐146b‐3p, hsa‐miR‐31‐5p, hsa‐miR‐9‐5p
  LOC441204      hsa‐miR‐138‐5p
  LOC93429       hsa‐miR‐138‐5p
  LRRC37A6P      hsa‐miR‐146b‐3p, hsa‐miR‐146b‐5p, hsa‐miR‐187‐3p, hsa‐miR‐199a‐3p, hsa‐miR‐221‐3p, hsa‐miR‐222‐5p, hsa‐miR‐508‐3p
  MIR31HG        hsa‐miR‐214‐3p
  MIR4697HG      hsa‐miR‐146b‐3p, hsa‐miR‐181a‐5p, hsa‐miR‐204‐5p, hsa‐miR‐221‐5p, hsa‐miR‐31‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐486‐5p, hsa‐miR‐7‐5p
  MIR9‐3HG       hsa‐miR‐146b‐3p, hsa‐miR‐214‐3p, hsa‐miR‐221‐5p, hsa‐miR‐31‐5p
  NR2F1‐AS1      hsa‐miR‐199b‐5p, hsa‐miR‐204‐5p,
  PLEKHA8P1      hsa‐miR‐204‐5p
  PRSS3P2        hsa‐miR‐34a‐5p
  PWAR5          hsa‐miR‐3065‐5p, hsa‐miR‐31‐5p
  RPSAP52        hsa‐miR‐222‐5p
  SMIM10L2A      hsa‐miR‐146b‐3p, hsa‐miR‐187‐3p, hsa‐miR‐214‐3p, hsa‐miR‐221‐5p, hsa‐miR‐34a‐5p, hsa‐miR‐9‐5p
  TINCR          hsa‐miR‐1247‐5p, hsa‐miR‐214‐3p
  TPTE2P1        hsa‐miR‐146b‐3p, hsa‐miR‐199b‐5p, hsa‐miR‐214‐3p, hsa‐miR‐3065‐5p, hsa‐miR‐7‐5p, hsa‐miR‐9‐5p
  YWHAEP7        hsa‐miR‐199b‐5p
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In the further analysis, the miRNA‐targeted mRNAs were predicted using TargetScan and miRTarBase. It was found that 30 miRNAs interacted with 130 mRNAs (Table [5](#cam41721-tbl-0005){ref-type="table"}). Then, we built a ceRNA network based on the above results (Tables [4](#cam41721-tbl-0004){ref-type="table"} and [5](#cam41721-tbl-0005){ref-type="table"}). Cytoscape 3.0 was performed to depict the ceRNA network (Figure [6](#cam41721-fig-0006){ref-type="fig"}). The ceRNA network contains 45 lncRNAs, 21 miRNAs, and 78 mRNAs finally.

###### 

miRNAs targeting PTC‐specific mRNAs

  miRNAs              mRNAs
  ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa‐miR‐1179        HDAC4, NCAM1, NRCAM, RUNX1, RUNX1T1, SGCD
  hsa‐miR‐138‐1‐3p    CCND1, CCND2, EFNB3, ENPP1, FUT9, GPR83
  hsa‐miR‐138‐5p      CTSH, EFNB3, ERBB4, EZH2, PLXNA4, PPARGC1A, RELN, SHANK2, SLC16A2, SLC17A7, SOX4, TCF7L1, TRPC5, UNC5A
  hsa‐miR‐144‐3p      ERBB4, FGF7, FOSB, GABRB2, IRS1, ITPR1, LRP2, PLXNC1, RARB, SMAD9
  hsa‐miR‐146b‐3p     CCND2, NRCAM, PPP1R1B, RUNX1T1, ERBB4, LRP2, MMP16, NOS1
  hsa‐miR‐181a‐2‐3p   EFNB3, ERBB4, GLS2, HPSE2, OPRK1, SLC17A7
  hsa‐miR‐181a‐5p     ACSL6, CDON, CYP26B1, DCN, EPHA5, FOS, NEGR1, PDGFRA, PRKG1, RPS6KA6, SHC3, SIPA1L2, SLC12A5, SLC26A4, TGFBR1, UNC5A
  hsa‐miR‐181b‐5p     ACSL6, BCL2, CDON, CYP26B1, DCN, GRIK2, GRIK3, HEY2, NEGR1, PDE5A, PDGFRA, PLAU, PRKG1, RPS6KA6, SHC3, SIPA1L2, SLC26A4, TBC1D4, TGFBR1, UNC5A
  hsa‐miR‐199a‐3p     DIO2, ERBB4, FN1, FUT9, RPS6KA6, SSX1
  hsa‐miR‐199b‐5p     ERBB4, GRIK3, HDAC9, PLXNC1, PPARGC1A, RUNX1T1, SEMA3F, SGCD, SOX4
  hsa‐miR‐204‐5p      AGPAT4, BCL2, CCND1, CCND2, CDH2, EPHA5, GABBR2, GPC3, PPARGC1A, RPS6KA5, RUNX2, SGCD, SLC22A3, TRPC5, UNC5B
  hsa‐miR‐214‐3p      BMP8A, FOSB, GRIN1, HPSE2, KCNJ13, NOS1, NTN1, OPRK1, PPARGC1A, PTCH2, RUNX1, RUNX1T1, SEMA3D, SGCD, SLIT1, SV2B
  hsa‐miR‐221‐3p      CDON, CXCL12, ERBB4, FOS, NCAM1, PLXNC1, SHANK2
  hsa‐miR‐221‐5p      ADRA1B, ALDH1A2, CCND1, DLG2, HRH1, PLCD3, PPP1R1B, RUNX1T1, SDC2, SHANK2, SLC6A1, TP63
  hsa‐miR‐222‐3p      CDON, CXCL12, DLG2, ERBB4, FOS, NCAM1
  hsa‐miR‐222‐5p      CD44, EGR1, EPHA5, FGF7, SDC2, TBC1D4, TNFRSF11B
  hsa‐miR‐3065‐5p     CTGF, DLG2, ERBB4, ETV5, FUT9, NLGN3, PTGFR, SLC17A7, SLIT1, SOX4
  hsa‐miR‐31‐3p       CYP1B1
  hsa‐miR‐31‐5p       CACNG4, FGF7, IL1RAP, NOS1, PLXNA4, RAPGEF5, SLC16A2
  hsa‐miR‐34a‐5p      ANK2, BCL2, CCNE2, DGKI, F2RL2, FOSB, FUT9, GABBR2, GAS1, MET, PDGFRA, RAP1GAP, RCAN1, SLC16A2, SLC6A1, SOX4
  hsa‐miR‐363‐3p      NOX4, SLC6A1, STEAP2, TP63
  hsa‐miR‐375         SLC16A2
  hsa‐miR‐486‐5p      EPHA3, GABRB3, SLC12A5, SRF
  hsa‐miR‐508‐3p      FGF7, HMGA2, RAPGEF5
  hsa‐miR‐509‐3p      ZMAT3
  hsa‐miR‐514a‐3p     AR
  hsa‐miR‐551b‐3p     ERBB4
  hsa‐miR‐7‐2‐3p      BCL2, ETV5, GABBR2, GAS1, HDAC9, PDE5A, PPP1R1A, SHANK2
  hsa‐miR‐7‐5p        CYTH3, EPHA3, IRS1, KCNJ2, SHANK2, SLIT1, WASF3, ZMAT3
  hsa‐miR‐9‐5p        ANK2, CCNE2, CNTFR, DIO2, DUSP6, ENTPD1, GABRB2, GRIK3, HMGA2, ID4, ITGB4, LIFR, MMP16, NOX4, PLXNA4, RPS6KA6, RUNX1, RUNX1T1, SDC2, SGCD, SHANK2, SHC3, SLC12A5, SLC39A14, TBC1D4, TNFRSF21
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![The lncRNA‐miRNA‐mRNA ceRNA network. Red diamonds represent upregulated miRNAs, red balls, upregulated mRNAs, and red cones, upregulated lncRNAs. Green diamonds represent downregulated miRNAs, green balls, downregulated mRNAs; green cones, downregulated lncRNAs](CAM4-7-5394-g006){#cam41721-fig-0006}

3.4. The association between clinical characteristics and PTC‐specific lncRNAs {#cam41721-sec-0013}
------------------------------------------------------------------------------

In the following analysis, the 45 specific lncRNAs identified in ceRNA network were evaluated to detect their clinical relevance, such as age, gender, race, lymphatic metastasis, TNM staging system, and patient outcome in TCGA database. It was found that a total of 37 specific lncRNAs expressed differentially correlated with PTC clinical features (*P* \< 0.05, Table [6](#cam41721-tbl-0006){ref-type="table"}). Seven lncRNAs (ATP6V0E2‐AS1, FOXD2‐AS1, LINC01257, EGFEM1P, MIR9‐3HG, MIR31HG, and FER1L4) were differentially expressed in age, 4 lncRNAs (YWHAEP7, LINC00887, MIR4697HG, and MIR9‐3HG) were differentially expressed in race, 1 lncRNA (LINC00887) was differentially expressed in gender, 30 lncRNAs (ATP6V0E2‐AS1, LINC00982, NR2F1‐AS1, LOC100126784, DPY19L2P4, FLJ23867, TINCR, ANKRD20A8P, EGOT, FAM95B1, LOC143666, MIR4697HG, LRRC37A6P, LOC100130238, MIR31HG, TPTE2P1, FAR2P1, LINC01257, FAM181A‐AS1, FLJ16779, EGFEM1P, LOC93429, GGT8P, FER1L4, GGT3P, ABCC6P1, LINC00284, KRTAP5‐AS1, FOXD2‐AS1, and HAND2‐AS1) were differently expressed in lymphatic metastasis, 31 lncRNAs (LINC00982, FLJ23867, ABCC6P1, FAM181A‐AS1, FOXD2‐AS1, NR2F1‐AS1, EGOT, TINCR, LRRC37A6P, LOC100126784, TPTE2P1, LOC100130238, FLJ16779, DPY19L2P4, GGT3P, MIR4697HG, MIR9‐3HG, ANKRD20A8P, SMIM10L2A, GGT8P, FAM95B1, KRTAP5‐AS1, LOC441204, GVINP1, LINC00887, MIR31HG, HAND2‐AS1, EGFEM1P, LOC93429, ATP6V0E2‐AS1, and LINC01257) were aberrantly expressed in different tumor sizes, and six lncRNAs (PLEKHA8P1, LOC100130238, GGT3P, MIR9‐3HG, LINC00284, and EGFEM1P) were differentially expressed in prognosis.

###### 

The correlations between PTC‐specific lncRNAs from ceRNA network and clinical features

  Comparisons                               Upregulation                                                                                                                                               Downregulation
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age (≥45 vs \<45 years old)               ATP6V0E2‐AS1, FOXD2‐AS1, LINC01257                                                                                                                         EGFEM1P, MIR9‐3HG, MIR31HG, FER1L4
  Race (white vs Asian)                     YWHAEP7, LINC00887                                                                                                                                         MIR4697HG, MIR9‐3HG
  Gender (male vs female)                   LINC00887                                                                                                                                                  
  Lymphatic metastasis (yes vs no)          NR2F1‐AS1, LOC100126784, FLJ23867, TINCR, EGOT, MIR31HG, FLJ16779, EGFEM1P, LOC93429, GGT8P, FER1L4, GGT3P, ABCC6P1, LINC00284, KRTAP5‐AS1, FOXD2‐AS1      ATP6V0E2‐AS1, LINC00982, DPY19L2P4, ANKRD20A8P, FAM95B1, LOC143666, MIR4697HG, LRRC37A6P, LOC100130238, TPTE2P1, FAR2P1, LINC01257, FAM181A‐AS1, HAND2‐AS1
  TNM staging system (T3 + T4 vs T1 + T2)   FLJ23867, ABCC6P1, FOXD2‐AS1, NR2F1‐AS1, EGOT, TINCR, LOC100126784, FLJ16779, GGT3P, GGT8P, KRTAP5‐AS1, LOC441204, LINC00887, MIR31HG, EGFEM1P, LOC93429   LINC00982, FAM181A‐AS1, LRRC37A6P, TPTE2P1, LOC100130238, DPY19L2P4, MIR4697HG, MIR9‐3HG, ANKRD20A8P, SMIM10L2A, FAM95B1, GVINP1, HAND2‐AS1, ATP6V0E2‐AS1, LINC01257
  Patient outcome (dead vs alive)           LOC100130238                                                                                                                                               PLEKHA8P1, GGT3P, MIR9‐3HG, LINC00284, EGFEM1P
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The univariate Cox proportional hazards regression model was performed to detect the prognostic value of 45 specific lncRNAs. We found that three specific lncRNAs closely related with PTC patient overall survival (OS, log‐rank *P* \< 0.05). There are two lncRNAs (GGT3P and KRTAP5‐AS1) positively relating to OS, and only one lncRNA (DPY19L2P4) negatively relating to OS (Figure [7](#cam41721-fig-0007){ref-type="fig"}).

![Kaplan--Meier survival curves for three lncRNAs associated with OS. Horizontal axis, OS time, days; vertical axis, survival function](CAM4-7-5394-g007){#cam41721-fig-0007}

3.5. qRT‐PCR validation {#cam41721-sec-0014}
-----------------------

Evaluation of randomly selected eight lncRNAs (LOC100130238, HAND2‐AS1, MIR9‐3HG, LOC143666, EGFEM1P, LINC00284, TINCR, and ABCC6P1) was performed to prove the reliability of the above bioinformatics analysis (Table [7](#cam41721-tbl-0007){ref-type="table"}). Firstly, the expression status of the eight specific lncRNAs was detected in 28 newly diagnosed patients with PTC using qRT‐PCR (Data [S2](#cam41721-sup-0002){ref-type="supplementary-material"}). Compared with paired normal thyroid tissues, four lncRNAs (LOC100130238, HAND2‐AS1, MIR9‐3HG, and LOC143666) were downregulated in PTC tumor tissues, whereas the remaining four lncRNAs (EGFEM1P, LINC00284, TINCR, and ABCC6P1) were upregulated in PTC tumor tissues (Figure [8](#cam41721-fig-0008){ref-type="fig"}). All the eight lncRNAs were aberrantly expressed with the same trend and reached statistical significance (*P* \< 0.05). Thus, the results were coherent with the above bioinformatics analysis. Subsequently, we performed the analysis of these eight lncRNAs and clinic features, and we found that HAND2‐AS1 was significantly related to tumor size (Figure [9](#cam41721-fig-0009){ref-type="fig"}, *P* \< 0.05). The result was identical with the analysis in TCGA database. Thus, our bioinformatics analysis is convincing based on the evaluation results.

###### 

Randomly selected lncRNAs with absolute fold change \>2.0, *P* \< 0.05

  Names (lncRNAs)   Gene ID     Regulation   Average FC
  ----------------- ----------- ------------ ------------
  LOC100130238      100130238   Down         9.69
  HAND2‐AS1         79804       Down         4.82
  MIR9‐3HG          254559      Down         4.44
  LOC143666         143666      Down         4.35
  EGFEM1P           93556       Up           6.94
  LINC00284         121838      UP           5.05
  TINCR             257000      Up           10.84
  ABCC6P1           653190      Up           7.69
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![Box plot showing the median and quartiles of specific lncRNAs in donor samples](CAM4-7-5394-g008){#cam41721-fig-0008}

![Box plot showing the association between the ΔΔCt of LOC100130238, HAND2‐AS1, MIR9‐3HG, LOC143666, EGFEM1P, LINC00284, TINCR and ABCC6P1 and clinicopathological characteristics in 28 PTC](CAM4-7-5394-g009){#cam41721-fig-0009}

4. DISCUSSION {#cam41721-sec-0015}
=============

Thyroid cancer is a common malignant endocrine disorder worldwide with increasing incidence in last few decades. According to the National Cancer Center, PTC is the most frequently diagnosed cancer among Chinese women before 30 years old.[31](#cam41721-bib-0031){ref-type="ref"} We cannot overlook the rapid rising in PTC, although the use of ultrasonography and fine needle aspiration in clinical may lead to overdiagnosis and overtreatment of PTC. In general, PTC has a relatively favorable prognosis; however, there are still about 5%‐10% of patients suffering from an aggressive form of PTC.[32](#cam41721-bib-0032){ref-type="ref"} Under such circumstances, thyroid cancer medicine is facing a huge challenge nowadays since concerns may cause overtreatment of PTC. Conventionally, risk evaluation for PTC is only based on clinicopathologic factors, such as age and lymphatic metastasis, which are definitely insufficient to accurately distinguish high‐risk patients from low‐risk patients. Thus, it is urgent to explore the underlying genetic background of PTC in order to identify the aggressive PTC and avoid overtreatment clinically. Research concerning the genetic regulatory mechanism in thyroid cancer has shown sustained development.

It is evident that aberrant expression of lncRNAs is closely related to oncogenesis in various cancer types.[33](#cam41721-bib-0033){ref-type="ref"} It is notable that lncRNAs are crucial in the genetic regulation and are responsible for cellular hemostasis.[34](#cam41721-bib-0034){ref-type="ref"}, [35](#cam41721-bib-0035){ref-type="ref"} Moreover, many studies showed that lncRNAs play an important part in tumorigenesis and are regulated by tumor suppressors or oncogenes transcriptionally. However, there are only a few studies focusing on lncRNAs in PTC using whole genome and transcriptome sequencing technologies,[18](#cam41721-bib-0018){ref-type="ref"}, [36](#cam41721-bib-0036){ref-type="ref"}, [37](#cam41721-bib-0037){ref-type="ref"} which demonstrated that dysregulated lncRNAs are essential in PTC carcinogenesis and may serve as diagnostic, prognostic biomarkers, and even therapeutic targets. Genomic analysis of PTC was firstly conducted using microarray in 2015 by Lan Xiabin et al,[21](#cam41721-bib-0021){ref-type="ref"} which identified thousands of differentially expressed lncRNAs and mRNAs in PTC tissues compared with normal thyroid cancer. Additionally, genomewide expression screening in 12 paired PTC tumor tissues and normal thyroid tissues identified 218 differentially expressed lncRNAs in PTC, and two lncRNAs (XLOC‐051122 and XLOC‐006074) were found closely related to lymphatic metastasis.[22](#cam41721-bib-0022){ref-type="ref"} Du et al[38](#cam41721-bib-0038){ref-type="ref"} have performed a genomewide analysis in 18 PTC patients' tissues and 4 healthy donors' tissues, and build the coexpression network of lncRNA--mRNA. By now, much is unknown about lncRNAs and mRNAs, or lncRNAs and miRNAs in PTC based on ceRNA hypothesis. The ceRNA network in cancer research has drawn increasing attention as it was proposed in 2011.[19](#cam41721-bib-0019){ref-type="ref"} It presented a hypothesis about how ceRNAs regulated other RNA transcripts by competing for miRNAs. It could be seen that ceRNA network has been built in many cancer types, such as colorectal cancer[39](#cam41721-bib-0039){ref-type="ref"} and lung cancer.[40](#cam41721-bib-0040){ref-type="ref"} These results indicate that lncRNAs prove to be significant in tumorigenesis.

TCGA is the largest cancer genetic information database to study the genomic profiles of PTC. The ceRNA (lncRNA‐miRNA‐mRNA) network of PTC was once constructed based on the 348 PTC samples in TCGA.[24](#cam41721-bib-0024){ref-type="ref"} In this study, dysregulated RNAs were identified in three PTC variants, including classical PTC, follicular PTC, and tall‐cell PTC. However, the study missed part of the data in TCGA and lacked laboratory‐based studies to validate the bioinformatics results. We aimed to identify the specific lncRNAs with diagnostic and prognostic roles in the study. Firstly, we retrieved the lncRNAs, miRNAs, and mRNAs profiles correlated with PTC stage and lymphatic metastasis in 461 PTC cases from TCGA database. Subsequently, the ceRNA network was built to predict the genetic interactions among the specific lncRNAs, miRNAs, and mRNAs. Next, we selected the intersected lncRNAs, miRNAs, and mRNAs in ceRNA network to assess their values in clinical relevance and prognosis based on the RNA sequencing data of 461 PTC samples and 55 normal samples. To validate the analysis results, the expression level of eight randomly selected lncRNAs (LOC100130238, HAND2‐AS1, MIR9‐3HG, LOC143666, EGFEM1P, LINC00284, TINCR, and ABCC6P1) was detected in 28 newly diagnosed tumor tissues and paired normal tissues in PTC patients using qRT‐PCR. The evaluation displayed the consistent trend of up‐ and downregulation of selected lncRNAs with the expression level in TCGA. Eventually, the clinical information of donor samples was collected and compared with the data of TCGA. Similarly, the clinical relevance of lncRNAs was consistent with that of TCGA.

We classified PTC patients in TCGA into four groups based on TNM staging and lymph node status. Then, we compared the RNA sequence data of tumor tissues with that of normal thyroid tissues. The intersected mRNAs were finally decided accordingly. GO enrichment analysis and KEGG pathway analysis of intersected mRNAs were performed to reveal the potential mRNA functions. The top 25 GO enrichment terms indicated metastasis‐associated functions, such as cell adhesion, proteolysis, and extracellular matrix organization. As for KEGG pathway analysis, top 25 pathways of intersected mRNAs included many cancer‐specific pathways, such as MAPK, PI3K/Akt, and p53 signaling pathway. The results were consistent with the integrated genomic analysis in TCGA which demonstrated in detail about the importance of somatic genetic mutations, such as BRAF and RAS mutation, in the MAPK and PI3K pathways in PTC.[41](#cam41721-bib-0041){ref-type="ref"} Many studies have shown that BRAF gene mutations increased the MAPK signaling pathway activation which could promote the initiation and development of PTC.[42](#cam41721-bib-0042){ref-type="ref"}, [43](#cam41721-bib-0043){ref-type="ref"}, [44](#cam41721-bib-0044){ref-type="ref"} Generally, BRAF gene mutations are linked to larger tumor size, multifocality, extrathyroid extension, and lymphatic metastasis and predict poor prognosis.[7](#cam41721-bib-0007){ref-type="ref"}, [45](#cam41721-bib-0045){ref-type="ref"}, [46](#cam41721-bib-0046){ref-type="ref"} It was reported that AZD6244, a MAPK pathway inhibitor, was strongly promising to treat thyroid cancer.[47](#cam41721-bib-0047){ref-type="ref"} As the second most common gene mutation in thyroid cancer, RAS mutation mainly activates PI3K/Akt pathway.[48](#cam41721-bib-0048){ref-type="ref"}, [49](#cam41721-bib-0049){ref-type="ref"} Moreover, many drugs, such as temsirolimus and everolimus, targeting PI3K/Akt have been investigated in phases I to III clinical trials and proven to be effective in treating thyroid cancer.[50](#cam41721-bib-0050){ref-type="ref"} In addition, abnormal p53 activation is closely related to the development of thyroid cancer.[51](#cam41721-bib-0051){ref-type="ref"}, [52](#cam41721-bib-0052){ref-type="ref"} In conclusion, the functional analysis was closely related to the development of PTC, which was also coherent with the classification standards.

A great number of studies have presented that lncRNAs may function as ceRNAs and play an essential role in regulating gene expression.[53](#cam41721-bib-0053){ref-type="ref"}, [54](#cam41721-bib-0054){ref-type="ref"}, [55](#cam41721-bib-0055){ref-type="ref"}, [56](#cam41721-bib-0056){ref-type="ref"} For instance, lncRNA H19 and HULC may act through a ceRNAs manner by regulating let‐7a/let‐7b and miR‐372/miR‐373 which play an essential part in cholangiocarcinoma development.[57](#cam41721-bib-0057){ref-type="ref"} We constructed ceRNA network of PTC with aberrantly expressed lncRNAs, miRNAs, and mRNAs in TCGA. Moreover, it was also found some cancer‐specific lncRNAs, such as LINC01140, LINC00261, ABHD11‐AS1, and TINCR,[58](#cam41721-bib-0058){ref-type="ref"}, [59](#cam41721-bib-0059){ref-type="ref"}, [60](#cam41721-bib-0060){ref-type="ref"}, [61](#cam41721-bib-0061){ref-type="ref"} served as important biomarkers in other different cancer types as well. We also found certain lncRNAs in ceRNAs played important roles in carcinogeneses, such as FOXD2‐AS, DLEU2, FER1L4, HAND2‐AS1, and TPTE2P1.[62](#cam41721-bib-0062){ref-type="ref"}, [63](#cam41721-bib-0063){ref-type="ref"}, [64](#cam41721-bib-0064){ref-type="ref"}, [65](#cam41721-bib-0065){ref-type="ref"}, [66](#cam41721-bib-0066){ref-type="ref"} Next, we analyzed the biologic functions and pathways of identified mRNAs in ceRNA network. The results revealed many important functions and pathways, including MAPK, PI3K/Akt, and p53 signaling pathway.

We analyzed the correlation of 45 PTC‐specific lncRNAs and clinic features, including age, race, gender, lymph node metastasis, TNM staging system, and patient outcome. The result showed that 37 specific lncRNAs were correlated with the above clinic characteristics. Eleven of these 37 lncRNAs have been reported to be closely related to various cancer types. For instance, lncRNA MIR31HG might function as an endogenous "sponge" for competing miR‐193b binding to regulate gene expression and promote tumor progression in pancreatic ductal adenocarcinoma.[67](#cam41721-bib-0067){ref-type="ref"} So far, there are few reports on the clinical relevance of these specific lncRNAs and PTC. More laboratory‐based work needs to be done to verify the interaction of lncRNAs, miRNAs, and mRNAs in PTC. Eventually, we also analyzed the association between these 45 lncRNAs with patient OS. It was found that six lncRNAs (LOC100130238, PLEKHA8P1, GGT3P, MIR9‐3HG, LINC00284, and EGFEM1P) were linked to PTC OS.

Subsequently, qRT‐PCR validation of 8 lncRNAs in 28 paired samples was performed to assess the credibility and accuracy of the bioinformatics results. The results of qRT‐PCR were consistent with the expression data in TCGA. Next, we assessed the clinical relevance of these eight lncRNAs based on our collected clinical information. The results suggested that HAND2‐AS1 was closely related to tumor size, which is in coherence with the results of TCGA analysis. Hence, the bioinformatics analysis results of our study are credible and convincing.

Our study intended to identify the specific lncRNAs in PTC and investigate their genetic regulation by constructing the ceRNA network. Moreover, the expression status and clinical relevance of identified lncRNAs from TCGA database were assessed and compared with the data of donor samples. Finally, the credibility of bioinformatics analysis results was demonstrated and confirmed by qRT‐PCR. Taken together, our results suggested that lncRNA‐related ceRNA network might play an important role in the initiation and development of PTC. We also hope that our study can inspire researchers in this field to carry out further work.
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